Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer
Open Access
- 25 January 2005
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 92 (3) , 553-561
- https://doi.org/10.1038/sj.bjc.6602374
Abstract
Vascular endothelial growth factor (VEGF) receptors consist of three cell-membrane type receptors (VEGFR-1, VEGFR-2 and VEGFR-3), and soluble form of VEGFR-1 (sVEGFR-1), an intrinsic negative counterpart of the VEGF. In this study, we measured intratumoral protein levels of free and total VEGF, VEGFR-2 and sVEGFR-1 from 202 primary breast cancer tissues and examined their prognostic values. A significant inverse correlation was found between free or total VEGF and oestrogen receptor (ER) status (P=0.042 and 0.032, respectively). A univariate analysis showed that low sVEGFR-1 and high total VEGF were significantly associated with poor prognosis in disease-free survival (DFS) and overall survival (OS). The ratio of sVEGFR-1 to total VEGF was a strong prognostic indicator (DFS: P=0.008; OS: P=0.0002). A multivariate analysis confirmed the independent prognostic values of total VEGF and the ratio of sVEGFR-1 to total VEGF. In subgroup analysis, total VEGF was a significant prognostic indicator for ER-positive tumours but not for ER-negative tumours, whereas sVEGFR-1 was significant for ER-negative tumours but not for ER-positive tumours. In conclusion, the intratumoral sVEGFR-1 level, VEGF level and the ratio of sVEGFR-1 to total VEGF are potent prognostic indicators of primary breast cancer, and might be relevant to ER status.Keywords
This publication has 29 references indexed in Scilit:
- Transduction of Soluble Flt-1 Gene to Peritoneal Mesothelial Cells Can Effectively Suppress Peritoneal Metastasis of Gastric CancerCancer Research, 2004
- Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromesCancer, 2004
- Circulating Angiogenic Factors and the Risk of PreeclampsiaNew England Journal of Medicine, 2004
- Vascular endothelial growth factor is associated with the efficacy of endocrine therapy in patients with advanced breast carcinomaCancer, 2003
- The biology of VEGF and its receptorsNature Medicine, 2003
- Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implicationsThe Lancet Oncology, 2001
- Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesisOncogene, 2000
- Prognostic Value of Vascular Endothelial Growth Factor in Breast CancerThe Oncologist, 2000
- Identification of a Natural Soluble Form of the Vascular Endothelial Growth Factor Receptor, FLT-1, and Its Heterodimerization with KDRBiochemical and Biophysical Research Communications, 1996
- Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor.Proceedings of the National Academy of Sciences, 1993